Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $70.32 Analyst target: $129.92 Upside: 84.76%
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to developing proprietary therapies to improve clinical outcomes for cancer patients in the United States. The company is headquartered in Wilmette, Illinois.
See the full interactive analysis & chart →Informational only — not investment advice.